~3 spots leftby Jan 2026

Rimegepant for Cluster Headache

Palo Alto (17 mi)
Overseen byCarrie Robertson, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: Mayo Clinic
No Placebo Group
Prior Safety Data
Approved in 6 jurisdictions

Trial Summary

What is the purpose of this trial?This trial is testing rimegepant, a medication that may help prevent cluster headaches. It targets patients who suffer from these severe headaches, especially those who don't respond well to other treatments. Rimegepant works by blocking pain signals in the brain. It was initially approved for treating migraines and is now being studied for preventing them.

Eligibility Criteria

This trial is for individuals with recurrent cluster headaches not caused by another disorder. Participants must have had MR imaging to rule out other causes, experience specific symptoms like severe unilateral pain and restlessness during attacks, and have a certain frequency of headaches. They can't join if they're near the end of a cluster cycle, have recent serious heart issues or are pregnant. Those on stable doses of certain headache medicines may be eligible.

Treatment Details

The study tests rimegepant's effectiveness as a preventive treatment for cluster headaches. It aims to see if taking rimegepant reduces the frequency or severity of headache episodes in participants who meet strict criteria based on their headache patterns and associated symptoms.
1Treatment groups
Experimental Treatment
Group I: Cluster Headache SubjectsExperimental Treatment1 Intervention
Subjects with cluster headaches will track their headaches for a one-week baseline headache diary. After establishing the baseline headache frequency, severity, and abortive medicine use, subjects will be asked to start their first dose of rimegepant with their next moderate to severe cluster headache.
Rimegepant is already approved in United States, European Union, Canada, United Kingdom for the following indications:
πŸ‡ΊπŸ‡Έ Approved in United States as Nurtec ODT for:
  • Acute treatment of migraine with or without aura in adults
  • Preventative treatment of episodic migraine in adults
πŸ‡ͺπŸ‡Ί Approved in European Union as Vydura for:
  • Prophylaxis and acute treatment of migraine in adults
πŸ‡¨πŸ‡¦ Approved in Canada as Nurtec ODT for:
  • Acute treatment of migraine with or without aura in adults
  • Preventative treatment of episodic migraine in adults
πŸ‡¬πŸ‡§ Approved in United Kingdom as Vydura for:
  • Prophylaxis and acute treatment of migraine in adults

Find a clinic near you

Research locations nearbySelect from list below to view details:
Mayo Clinic RochesterRochester, MN
Loading ...

Who is running the clinical trial?

Mayo ClinicLead Sponsor

References